查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1952768

環肽市場：按類型、產品類型、技術、應用和最終用戶分類，全球預測（2026-2032年）

Cyclic Peptides Market by Type, Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，循環胜肽市值將達到 33.6 億美元，到 2026 年將成長至 35.7 億美元，到 2032 年將達到 52.7 億美元，年複合成長率為 6.63%。

關鍵市場統計數據
基準年 2025 33.6億美元
預計年份：2026年 35.7億美元
預測年份 2032 52.7億美元
複合年成長率 (%) 6.63%

透過跨學科創新、跨領域合作和不斷變化的臨床需求動態，開闢環肽研究的新領域

環肽因其結構剛性、增強的穩定性和對難標靶的高親和性，已成為一類變革性的治療藥物。其獨特的環狀骨架賦予其抵抗蛋白水解的能力，使其成為從腫瘤和代謝性疾病到感染疾病和診斷平台等廣泛應用領域的理想候選藥物。過去十年，合成調查方法和生物技術創新的快速發展，為以前所未有的精度設計環肽結構鋪平了道路，加速了先導化合物的發現和最佳化。

創新技術進步和合作突破正在重新定義全球環肽研發的發展軌跡。

近年來，環肽領域發生了模式轉移，最尖端科技和戰略合作的融合加速了藥物發現和開發。自動化合成平台結合先進的純化通訊協定，顯著縮短了生產前置作業時間並提高了產率。同時，機器學習在分子建模的應用改善了標靶結合預測，先導藥物最適化，並降低了後期研發失敗的風險。

分析2025年美國關稅調整對環肽產業生態系和市場韌性的廣泛影響

美國將於2025年實施的新關稅政策，為環肽相關人員帶來了複雜的策略考量。國際採購的原料、特殊試劑和關鍵中間體均面臨更高的進口關稅，促使企業對籌資策略進行全面審查。許多企業正透過多元化供應商、尋求近岸外包以及投資國內生產能力來應對這項挑戰，以降低關稅波動帶來的風險。

關鍵細分市場分析揭示了環肽領域按類型、方法、應用和最終用戶觀點的市場動態

對市場區隔的詳細分析揭示了多維度上的微妙動態。就結構分類而言，天然來源的環肽因其固有的生物活性和已確立的安全性而保持著強大的吸引力，而合成類似物則因其可調控的性質和更廣泛的化學多樣性而備受關注。這種雙重性平衡了研究重點，天然類似物通常可作為合成最佳化的藍圖。

評估影響美洲、歐洲、中東和非洲以及亞太地區環肽市場開發和商業化的區域趨勢

環肽領域的區域發展趨勢在美洲、歐洲、中東和非洲以及亞太地區之間存在顯著差異，從而形成了各自獨特的研發和商業化路徑。在美洲，對胜肽創新中心的大力投資和支持性的管理方案正在促進從研究到臨床的快速轉化，許多生物技術公司正在建立合作夥伴關係以加速生產規模的擴大。

產業領導者簡介：擁有獨特創新產品組合的公司，以及推動環肽市場發展的策略聯盟

對領先企業的分析揭示了推動環肽領域成長的多元化策略方法。製藥公司正透過策略聯盟將先進的胜肽平台整合到其產品線中，這些聯盟利用了公司內部的固相合成能力，並獲得了新興的重組和混合技術。這些聯盟通常圍繞著共同開發契約、共用生產網路和聯合知識產權組合展開，從而加快產品上市速度。

策略建議，助您掌握循環胜肽領域的新興機遇，鞏固市場地位

為了掌握環肽市場的新機遇，產業領導者應採取多元化策略，平衡創新、卓越營運和市場應對力。首先，投資於整合固相、混合和重組DNA技術的多元化平台，能夠快速適應不斷變化的計劃需求，從簡單的類似物到複雜的環狀大分子。

調查方法透明化：將一手研究（專家訪談）與二手研究資料整合相結合，以產生關於環肽的可靠知識。

本分析採用嚴謹的多階段調查方法，以確保其準確性、相關性和可操作性。首先，透過對同行評審文章、專利資料庫、監管文件和權威產業報告等二手資料的總結研究，建構了全面的資訊基礎，涵蓋了技術進步、安全性概況和應用趨勢等資訊來源。

全面審視環肽這一新興領域的發展軌跡和塑造未來成長的策略要務

整體而言，環肽處於創新化學技術、卓越生物技術和臨床需求的交匯點。它們在生命科學領域的多方面應用，涵蓋先進治療方法和診斷、環境保護和研究工具等，凸顯了其戰略重要性。合成技術的不斷進步，加上計算設計和監管支持，正推動該領域邁向新的高度。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：環肽市場（按類型分類）

  • 天然環肽
  • 合成環肽

9. 環肽市場（依產品類型分類）

  • 抗菌胜肽
    • Daptomycin
    • 短桿菌肽S
    • 酪胺酸
  • 荷爾蒙胜肽
    • 催產素
    • 生長抑制素
    • 增壓素
  • 免疫調節胜肽
  • 胜肽疫苗

第10章：環肽市場（依技術分類）

  • 化學合成
  • 液相合成
  • 重組DNA技術
  • 固相合成

第11章 環肽市場按應用領域分類

  • 農業
  • 化妝品
  • 診斷
    • 生物感測器
    • 免疫檢測
  • 研究與開發
    • 生化分析
    • 藥物發現
    • 分子生物學
  • 治療藥物
    • 循環系統
    • 感染疾病
    • 代謝性疾病
    • 腫瘤學

第12章 環肽市場（依最終用戶分類）

  • 學術機構
  • 生技公司
  • 製藥公司

第13章：環胜肽市場區域概覽

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：環肽市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國環肽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國環胜肽市場

第17章：中國環肽市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca PLC
  • Aurigene Pharmaceutical Services by Dr. Reddy's Laboratories Ltd.
  • Bachem AG
  • Bicycle Therapeutics plc
  • BioDuro LLC
  • Biopharma PEG Scientific Inc
  • Biosynth Ltd.
  • Clariant AG
  • Corden Pharma International GmbH
  • CPC Scientific Inc.
  • Creative Peptides, Inc.
  • Eli Lilly and Company
  • Genscript Biotech Corporation
  • JPT Peptide Technologies GmbH
  • Kaneka Corporation
  • LifeTein LLC
  • Merck & Co., Inc.
  • Neuland Laboratories Ltd
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SciTide LLC
  • TCG Lifesciences Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Zealand Pharma A/S
Product Code: MRR-AE420CB152AD

The Cyclic Peptides Market was valued at USD 3.36 billion in 2025 and is projected to grow to USD 3.57 billion in 2026, with a CAGR of 6.63%, reaching USD 5.27 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.36 billion
Estimated Year [2026] USD 3.57 billion
Forecast Year [2032] USD 5.27 billion
CAGR (%) 6.63%

Forging New Frontiers in Cyclic Peptide Research Through Interdisciplinary Innovation, Cross-Sector Collaboration, and Evolving Clinical Demand Dynamics

Cyclic peptides have emerged as a transformative class of therapeutic agents, distinguished by their structural rigidity, enhanced stability, and high binding affinity to challenging targets. Their unique macrocyclic framework confers resistance to proteolytic degradation, rendering them ideal candidates for applications ranging from oncology and metabolic disorders to infectious diseases and diagnostic platforms. Over the past decade, rapid advances in synthetic methodologies and biotechnological innovation have unlocked pathways to tailor cyclic peptide structures with unprecedented precision, accelerating lead identification and optimization.

Beyond therapeutic applications, cyclic peptides are increasingly leveraged in environmental protection and research domains. Their specificity and biocompatibility make them valuable tools for biochemical analysis, molecular biology, and biosensing systems. As the convergence of computational design, novel synthesis techniques, and scalable manufacturing reshapes the landscape, stakeholders across academia, biotechnology firms, and pharmaceutical companies are collaborating to harness these molecules' full potential.

Against this backdrop, the present report delivers a comprehensive exploration of industry dynamics, regulatory frameworks, and emerging regional trends. It highlights how advancements in solid-phase synthesis, hybrid technologies, and recombinant DNA methods are driving the next wave of innovation. By examining market segmentation across type, product, technology, application, and end user, decision makers will acquire a holistic view of the cyclic peptide ecosystem and its future trajectory.

Revolutionary Technological Advances and Collaborative Breakthroughs Redefining the Cyclic Peptide Research and Development Trajectory Globally

Recent years have witnessed a paradigm shift in the cyclic peptide domain, as cutting-edge technologies and strategic partnerships converge to accelerate discovery and development. Automation in synthetic platforms, coupled with enhanced purification protocols, has significantly reduced production timelines and increased yield consistency. Meanwhile, the integration of machine learning into molecular modeling has improved target engagement predictions, thereby streamlining lead optimization and mitigating late-stage failures.

Collaborations between academic institutes and industry players have further catalyzed progress. Joint ventures focused on hybrid synthesis approaches and liquid-phase methods are expanding the toolbox for peptide assembly, balancing cost-efficiency with scalability. In parallel, advancements in recombinant DNA technology enable the expression of complex cyclic structures in microbial hosts, unlocking access to novel analogs and post-translational modifications previously deemed infeasible.

On the regulatory front, agencies have introduced guidance frameworks to support peptide therapeutics, fostering expedited review pathways for candidates addressing high-unmet medical needs. This evolving ecosystem underscores the importance of adaptive R&D strategies that embrace platform flexibility, digital integration, and cross-disciplinary expertise. As the industry transitions from proof-of-concept studies to clinical translation, these transformative shifts are redefining the pace and scope of cyclic peptide innovation globally.

Analyzing the Far-Reaching Consequences of United States Tariff Adjustments in 2025 on the Cyclic Peptide Industry Ecosystem and Market Resilience

The implementation of new United States tariffs in 2025 has introduced a complex layer of strategic considerations for cyclic peptide stakeholders. Raw materials, specialized reagents, and critical intermediates sourced internationally have become subject to increased import duties, prompting a comprehensive reevaluation of sourcing strategies. Many organizations have responded by diversifying supplier bases, pursuing near-shoring options, and investing in domestic manufacturing capabilities to mitigate exposure to tariff fluctuations.

Although these adjustments have introduced upward pressure on input costs, they have simultaneously spurred innovation in process efficiency. Companies are optimizing solid-phase synthesis protocols and exploring alternative chemistries that reduce reliance on tariff-sensitive reagents. This has fostered the emergence of novel hybrid technologies and liquid-phase strategies that deliver competitive cost structures without compromising product quality.

At the same time, the heightened focus on supply chain resilience has accelerated collaborations between contract manufacturers and technology developers. By leveraging recombinant DNA platforms and modular production facilities, stakeholders are building flexible networks capable of rapid scale-up and geographic redistribution. These efforts underscore a broader industry trend: converting trade policy challenges into drivers of localized innovation and long-term stability in cyclic peptide development and manufacturing.

Unveiling Critical Segmentation Insights Illuminating Market Dynamics Across Types Methods Applications and End User Perspectives in Cyclic Peptide Domain

An in-depth examination of market segmentation reveals nuanced dynamics across multiple dimensions. In terms of structural classification, naturally derived cyclic peptides maintain strong appeal due to their inherent bioactivity and established safety profiles, while synthetic variants gain traction for their tunable properties and expanded chemical diversity. This duality drives a balanced research focus, with natural analogs often serving as blueprints for synthetic optimization.

When considering product categories, antimicrobial cyclic peptides command significant interest as potential alternatives to traditional antibiotics, with flagship compounds such as daptomycin, gramicidin S, and tyrocidine undergoing rigorous evaluation against resistant strains. Hormonal peptides, including oxytocin, somatostatin, and vasopressin, continue to underpin established therapies, even as immunomodulating peptides and innovative peptide vaccines progress through advanced discovery pipelines.

From a technological standpoint, solid-phase synthesis remains a workhorse for routine production, whereas recombinant DNA technology and hybrid approaches are unlocking access to complex cyclization patterns and post-translational modifications. Liquid-phase methods are similarly evolving, offering streamlined workflows for select chemistries. Applications across diagnostics, environmental protection, research and development, and therapeutics illustrate the versatility of cyclic peptides, with biosensors, immunoassays, biochemical analysis, drug discovery, molecular biology, cardiovascular therapies, infectious disease treatments, metabolic disorder interventions, and oncology programs each reflecting distinct development pathways.

End users span academic research centers, biotechnology firms advancing early innovation, and pharmaceutical companies focused on late-stage development and commercialization. This layered segmentation underscores the importance of targeted strategies that align platform capabilities with specific market demands and regulatory landscapes.

Evaluating Distinct Regional Dynamics Shaping Cyclic Peptide Development and Commercialization Across Americas Europe Middle East Africa and Asia Pacific Markets

Regional trends in the cyclic peptide domain vary significantly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, shaping distinct development and commercialization pathways. Within the Americas, robust investment in peptide innovation hubs and supportive regulatory initiatives have fostered rapid progression from bench to clinic, with many biotechnology firms establishing partnerships to expedite manufacturing scale-up.

In the Europe, Middle East & Africa region, a combination of stringent regulatory standards and collaborative consortia has driven emphasis on safety, efficacy, and harmonized approval processes. These dynamics have encouraged pharmaceutical companies to invest in cross-border alliances, leveraging local expertise in both chemical synthesis and recombinant platforms to address region-specific health challenges.

Meanwhile, Asia-Pacific has emerged as a hotspot for cost-effective manufacturing and high-throughput screening capabilities. Government-led research programs and incentives for biotechnology development have accelerated adoption of hybrid and liquid-phase synthesis methods, while contract development and manufacturing organizations expand capacity to serve global clients.

These regional insights highlight the importance of customizable strategies that account for differing regulatory regimes, reimbursement frameworks, and infrastructure maturity. By aligning R&D investments with local capabilities and policy incentives, stakeholders can optimize market entry, accelerate clinical translation, and build resilient supply chains across diverse geographies.

Profiling Key Industry Leaders Showcasing Distinct Innovative Portfolios Strategic Collaborations Propelling the Cyclic Peptide Market Forward

A focused review of leading organizations reveals diverse strategic approaches driving growth in the cyclic peptide sphere. Several pharmaceutical corporations have integrated advanced peptide platforms into their pipelines, leveraging in-house capabilities for solid-phase synthesis alongside strategic collaborations to access emerging recombinant and hybrid technologies. These alliances often center on co-development agreements, shared manufacturing networks, and joint IP portfolios that enhance speed to market.

Biotechnology firms specializing in cyclic peptides have differentiated themselves through vertical integration of discovery and process development functions. By maintaining end-to-end control over design, synthesis, and analytical characterization, these companies accelerate candidate progression while ensuring stringent quality attributes. Investments in automation and digital analytics further enable real-time process monitoring, reducing batch variability and enhancing reproducibility.

Contract development and manufacturing organizations, recognizing the complexity of cyclic peptide production, have expanded dedicated facilities and technical expertise to support both small- and large-scale projects. Their service portfolios now routinely include custom synthesis, purification, and formulation services tailored to macrocyclic structures, with expertise spanning antimicrobial compounds, hormonal analogs, and novel immunomodulators.

This competitive landscape underscores the imperative for continuous innovation in platform technologies, strategic partnerships, and capacity expansion. Organizations that harmonize scientific excellence with operational agility are best positioned to capture emerging opportunities and deliver next-generation cyclic peptide therapeutics.

Strategic Recommendations Empowering Industry Leaders to Capitalize on Emerging Opportunities and Strengthen Market Positions in Cyclic Peptide Sector

To capitalize on emerging opportunities in the cyclic peptide market, industry leaders should pursue a multipronged strategy that balances innovation, operational excellence, and market responsiveness. First, investing in platform diversification-integrating solid-phase, hybrid, and recombinant DNA technologies-will enable rapid adaptation to evolving project requirements, from simple analogs to complex macrocycles.

Second, strengthening supply chain resilience is essential. This can be achieved by establishing regional manufacturing hubs, forging partnerships with domestic suppliers to mitigate tariff exposure, and implementing advanced process controls that reduce material waste and enhance reproducibility. Collaborative networks with contract manufacturers and academic centers can further buffer against disruptions and accelerate technology transfer.

Third, aligning product portfolios with high-unmet medical needs and emerging regulatory incentives will foster smoother clinical pathways. Prioritizing antimicrobial resistance, targeted oncology applications, and novel peptide vaccines can attract expedited review mechanisms and public-private funding opportunities. Simultaneously, extending applications into diagnostics and environmental monitoring can diversify revenue streams and build long-term market resilience.

Finally, adopting digital tools-from machine learning-based design algorithms to real-time analytics in manufacturing-will optimize R&D and production workflows. By combining data-driven insights with cross-functional collaboration models, organizations can reduce development timelines, enhance quality, and sustain competitive differentiation in the cyclic peptide landscape.

Transparency in Methodological Rigor Combining Primary Research Expert Interviews and Secondary Data Synthesis to Generate Robust Insights on Cyclic Peptides

This analysis was constructed using a rigorous, multi-stage research methodology designed to ensure accuracy, relevance, and actionable insights. Initially, secondary research aggregated information from peer-reviewed publications, patent databases, regulatory filings, and authoritative industry reports. These sources provided a broad foundation of technological advancements, safety profiles, and application trends.

Subsequently, primary research involved in-depth interviews with a diverse panel of experts, including R&D leads at pharmaceutical firms, process development specialists at biotechnology companies, and regulatory consultants. These discussions illuminated practical challenges in scale-up, emerging tariff impacts, and regional regulatory nuances, yielding qualitative perspectives that enriched quantitative data.

Data synthesis employed triangulation techniques, cross-validating findings from multiple sources to minimize bias and enhance reliability. Market segmentation matrices were developed by systematically categorizing insights across structural type, product category, technology platform, application area, and end-user profile. Regional analysis incorporated economic indicators, policy frameworks, and investment trends to contextualize geographic opportunities.

Through this comprehensive approach-blending secondary intelligence with primary expert validation-the report delivers a robust framework for decision makers to navigate the dynamic cyclic peptide ecosystem with confidence.

Concluding Perspectives on the Evolutionary Trajectory and Strategic Imperatives Shaping Future Growth in the Expanding Cyclic Peptide Landscape

In summation, cyclic peptides stand at the intersection of innovative chemistry, biotechnological prowess, and clinical necessity. Their multifaceted applications-from advanced therapeutics and diagnostics to environmental protection and research tools-underscore their strategic importance across the life sciences sector. The ongoing evolution of synthesis technologies, coupled with computational design and regulatory support, is propelling the field toward new horizons.

Challenges such as supply chain disruptions and tariff adjustments have prompted the industry to embrace flexibility, driving investments in domestic manufacturing and diversified supplier networks. Simultaneously, segmentation insights reveal that tailored strategies aligned with specific product types, technological platforms, and end-user requirements are critical for sustained growth.

Regionally, adaptive approaches that reflect local regulatory environments and infrastructure capabilities will be key to unlocking market potential in the Americas, Europe, Middle East & Africa, and Asia-Pacific. Moreover, the competitive landscape favors organizations that combine deep scientific expertise with operational agility and strategic partnerships.

Looking ahead, stakeholders that integrate data-driven decision making, platform diversification, and collaborative innovation will be best equipped to navigate complexity and seize opportunities in the expanding cyclic peptide arena. This report provides the foundational insights required to chart a path toward robust, long-term success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cyclic Peptides Market, by Type

  • 8.1. Natural Cyclic Peptide
  • 8.2. Synthetic Cyclic Peptide

9. Cyclic Peptides Market, by Product Type

  • 9.1. Antimicrobial Peptides
    • 9.1.1. Daptomycin
    • 9.1.2. Gramicidin S
    • 9.1.3. Tyrocidine
  • 9.2. Hormonal Peptides
    • 9.2.1. Oxytocin
    • 9.2.2. Somatostatin
    • 9.2.3. Vasopressin
  • 9.3. Immunomodulating Peptides
  • 9.4. Peptide Vaccines

10. Cyclic Peptides Market, by Technology

  • 10.1. Chemical Synthesis
  • 10.2. Liquid-Phase Synthesis
  • 10.3. Recombinant DNA Technology
  • 10.4. Solid-Phase Synthesis

11. Cyclic Peptides Market, by Application

  • 11.1. Agriculture
  • 11.2. Cosmetics
  • 11.3. Diagnostics
    • 11.3.1. Biosensors
    • 11.3.2. Immunoassays
  • 11.4. Research & Development
    • 11.4.1. Biochemical Analysis
    • 11.4.2. Drug Discovery
    • 11.4.3. Molecular Biology
  • 11.5. Therapeutics
    • 11.5.1. Cardiovascular
    • 11.5.2. Infectious Diseases
    • 11.5.3. Metabolic Disorders
    • 11.5.4. Oncology

12. Cyclic Peptides Market, by End User

  • 12.1. Academic Institutes
  • 12.2. Biotechnology Firms
  • 12.3. Pharmaceutical Companies

13. Cyclic Peptides Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cyclic Peptides Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cyclic Peptides Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cyclic Peptides Market

17. China Cyclic Peptides Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AstraZeneca PLC
  • 18.6. Aurigene Pharmaceutical Services by Dr. Reddy's Laboratories Ltd.
  • 18.7. Bachem AG
  • 18.8. Bicycle Therapeutics plc
  • 18.9. BioDuro LLC
  • 18.10. Biopharma PEG Scientific Inc
  • 18.11. Biosynth Ltd.
  • 18.12. Clariant AG
  • 18.13. Corden Pharma International GmbH
  • 18.14. CPC Scientific Inc.
  • 18.15. Creative Peptides, Inc.
  • 18.16. Eli Lilly and Company
  • 18.17. Genscript Biotech Corporation
  • 18.18. JPT Peptide Technologies GmbH
  • 18.19. Kaneka Corporation
  • 18.20. LifeTein LLC
  • 18.21. Merck & Co., Inc.
  • 18.22. Neuland Laboratories Ltd
  • 18.23. Novartis AG
  • 18.24. Pfizer Inc.
  • 18.25. Sanofi S.A.
  • 18.26. SciTide LLC
  • 18.27. TCG Lifesciences Pvt. Ltd.
  • 18.28. Thermo Fisher Scientific Inc.
  • 18.29. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYCLIC PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYCLIC PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CYCLIC PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY NATURAL CYCLIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY NATURAL CYCLIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY NATURAL CYCLIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY GRAMICIDIN S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY GRAMICIDIN S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY GRAMICIDIN S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYROCIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYROCIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYROCIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY OXYTOCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY OXYTOCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY OXYTOCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOMATOSTATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOMATOSTATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOMATOSTATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY VASOPRESSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY VASOPRESSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOMODULATING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOMODULATING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOMODULATING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COSMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COSMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COSMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY MOLECULAR BIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY MOLECULAR BIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY MOLECULAR BIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. GCC CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 254. G7 CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. NATO CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 261. NATO CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 265. NATO CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA CYCLIC PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)